Federal Circuit Won't Rehear Celebrex Patent Dispute
A federal appeals court will not revisit its March decision that prevents Teva Pharmaceuticals USA Inc. from launching a generic copy of Pfizer Inc.'s painkiller Celebrex for the next six years....To view the full article, register now.
Already a subscriber? Click here to view full article